Sarcoma最新文献

{"title":"Testicular, Spermatic Cord, and Scrotal Soft Tissue Sarcomas: Treatment Outcomes and Patterns of Failure.","authors":"Varun K Chowdhry, John M Kane, Katy Wang, Daniel Joyce, Anne Grand'Maison, Gary N Mann","doi":"10.1155/2021/8824301","DOIUrl":"10.1155/2021/8824301","url":null,"abstract":"<p><strong>Introduction: </strong>Paratesticular sarcomas are defined as tumors that arise within the scrotum and include the subsites of epididymis, spermatic cord, and tunica vaginalis and represent the most common type of GU sarcoma. The mainstay of treatment is often surgical resection, combined with histology specific chemotherapy and radiotherapy. Due to the rare nature of the disease, there are limited data to guide management. We present our single-institution retrospective experience regarding the management and treatment of paratesticular sarcomas.</p><p><strong>Materials and methods: </strong>We queried our oncology registry database for patients treated for testicular, spermatic cord, and scrotal soft tissue sarcomas between 1971 and 2017. Patients in this series had pathological confirmation of a sarcoma diagnosis by a sarcoma-specialized pathologist. Only patients with localized disease were included in this analysis with the exception of patients with a diagnosis of rhabdomyosarcoma where patients with both localized and metastatic disease were included on this study.</p><p><strong>Results: </strong>A total of 34 patients were included in this retrospective analysis. The median was 24 (range, 5-78), and the median tumor size was 6.25 cm. Twenty-six patients had localized disease (76.6%) at the time of diagnosis. A predominance of patients had tumors involving the spermatic cord (45.5%), and the most common histology was rhabdomyosarcoma (35.3%), leiomyosarcoma (26.5%), and well-differentiated liposarcoma (23.5%). The median follow-up was 71.0 months (range, 2.5-534.4 months). A total of 7 patients experienced an isolated local failure (20.6%), four patients developed distant metastatic disease (11.8%), and one patient (2.9%) with synovial sarcoma of the spermatic cord experienced a regional recurrence. The median progression-free survival (PFS) was 99.6 months, 95% CI (45.8-534.3 months), with a three-year PFS rate of 71%, 95% CI (53%-83%), and a 5-year PFS rate of 64% (range, 46%-78%). We did not find any statistically significant associations based on surgery type (<i>p</i>=0.15), the use of chemotherapy, (<i>p</i>=0.36), or final margin status (<i>p</i>=0.21). Two patients who were treated with preoperative radiotherapy had significant wound healing complication with chronic sinus tracts, though these patients did not experience a local recurrence.</p><p><strong>Conclusions: </strong>We provide a characterization of the natural history and treatment patterns of paratesticular sarcomas. While effective at reducing a local recurrence, preoperative radiotherapy was associated with significant toxicity. As a result, we prefer the use of postoperative radiotherapy in patients as clinically indicated. We did not find any specific treatment patterns associated with an improvement in clinical outcomes.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2021 ","pages":"8824301"},"PeriodicalIF":0.0,"publicationDate":"2021-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25500530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma.","authors":"Yoav Zvi,&nbsp;Elif Ugur,&nbsp;Brian Batko,&nbsp;Jonathan Gill,&nbsp;Michael Roth,&nbsp;Richard Gorlick,&nbsp;David Hall,&nbsp;Janet Tingling,&nbsp;Donald A Barkauskas,&nbsp;Jinghang Zhang,&nbsp;Rui Yang,&nbsp;Bang H Hoang,&nbsp;David S Geller","doi":"10.1155/2021/8324348","DOIUrl":"https://doi.org/10.1155/2021/8324348","url":null,"abstract":"<p><strong>Background: </strong>Six cell surface receptors, human epidermal growth factor receptor-2 (Her-2), platelet-derived growth factor receptor-<i>β</i> (PDGFR-<i>β</i>), insulin-like growth factor-1 receptor (IGF-1R), insulin receptor (IR), c-Met, and vascular endothelial growth factor receptor-3 (VEGFR-3), previously demonstrated variable expression across varying patient-derived and standard osteosarcoma (OS) cell lines. The current study sought to validate previous expression patterns and evaluate whether these receptors offer prognostic and/or therapeutic value.</p><p><strong>Methods: </strong>Patient-derived OS cell lines (<i>n</i> = 52) were labeled with antibodies to Her-2, PDGFR-<i>β</i>, IGF-1R, IR, c-Met, and VEGFR-3. Expression was characterized using flow cytometry. The difference in geometric mean fluorescent intensity (geoMFI_diff = geoMFI_positive - geoMFI_negative) was calculated for each receptor across all cell lines. Receptor expression was categorized as low (Q1), intermediate (Q2, Q3), or high (Q4). The event-free survival (EFS) and overall survival for the six cell surface receptors were estimated by the Kaplan-Meier method. Differences in hazard for EFS event and overall survival event for patients in each of the three expression levels in each of the six cell surface receptors were assessed using the log-rank test.</p><p><strong>Results: </strong>All 6 receptors were variably expressed in the majority of cell lines. IR and PDGFR-<i>β</i> expressions were found to be significant predictors for EFS amongst patients with nonmetastatic disease (<i>p</i>=0.02 and 0.01, respectively). The hazard ratio for EFS was significantly higher between high IR and intermediate IR expression (HR = 2.66, <i>p</i>=0.02), as well as between high PDGFR-<i>β</i> and intermediate PDGFR-<i>β</i> expression (HR = 5.68, <i>p</i>=0.002). Her-2, c-Met, IGF-1R, and VEGFR-3 were not found to be significant predictors for either EFS or overall survival.</p><p><strong>Conclusion: </strong>The six cell surface receptors demonstrated variable expression across the majority of patient-derived OS cell lines tested. Limited prognostic value was offered by IR and PDGFR-<i>β</i> expression within nonmetastatic patients. The remaining receptors do not provide clear prognostic utility. Nevertheless, their consistent, albeit variable, surface expression across a large panel of patient-derived OS cell lines maintains their potential use as future therapeutic targets.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2021 ","pages":"8324348"},"PeriodicalIF":0.0,"publicationDate":"2021-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25387250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis\".","authors":"P Schöffski,&nbsp;I Timmermans,&nbsp;D Hompes,&nbsp;M Stas,&nbsp;Veerle Boecxstaens,&nbsp;F Sinnaeve,&nbsp;P De Leyn,&nbsp;W Coosemans,&nbsp;D Van Raemdonck,&nbsp;E Hauben,&nbsp;R Sciot,&nbsp;P Clement,&nbsp;O Bechter,&nbsp;B Beuselinck,&nbsp;F J S H Woei-A-Jin,&nbsp;H Dumez,&nbsp;P Nafteux,&nbsp;T Wessels","doi":"10.1155/2021/4653987","DOIUrl":"https://doi.org/10.1155/2021/4653987","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1155/2020/1385978.].</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2021 ","pages":"4653987"},"PeriodicalIF":0.0,"publicationDate":"2021-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25402253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcoma of the Breast: Clinical Characteristics and Outcomes of 991 Patients from the National Cancer Database.","authors":"Jin Sun Lee,&nbsp;Kevin Yoon,&nbsp;Mykola Onyshchenko","doi":"10.1155/2021/8828158","DOIUrl":"https://doi.org/10.1155/2021/8828158","url":null,"abstract":"<p><strong>Background: </strong>Sarcoma of the breast is a rare malignancy with heterogeneous histology. Angiosarcoma, including secondary angiosarcoma from previous radiation, is the most common type of sarcoma of the breast. Other types of sarcomas of the breast have limited clinical and survival information.</p><p><strong>Methods: </strong>We obtained clinicopathological data and survival outcomes from the patients with sarcoma of the breast, excluding angiosarcoma, that were registered in the National Cancer Database (NCDB) from 2004 to 2016. The treatment patterns and prognostic factors were analyzed.</p><p><strong>Results: </strong>A total of 991 patients had sarcoma of the breast other than angiosarcoma. The most common histology was spindle cell sarcoma (13.4%), followed by leiomyosarcoma (11.7%) and giant cell sarcoma (10.1%). Surgical resection was performed in 894 out of 991 patients (90.2%), including R0 resection achieved in 781 (87.4%). The patients who received surgery showed better survival than the patients without surgery regardless of radiation therapy. When radiation was added to the surgical management, the OS (overall survival) benefit was marginally significant (hazard ratio 1.30 (CI 1.01-1.67), <i>p</i>=0.044). Adding chemotherapy did not improve OS.</p><p><strong>Conclusions: </strong>Surgical resection seems to be the most important treatment modality in sarcoma of the breast from the analysis of a large database. Radiation therapy added a minor survival benefit to the patients who received surgical resection. Systemic chemotherapy did not play a clear role in sarcoma of the breast.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2021 ","pages":"8828158"},"PeriodicalIF":0.0,"publicationDate":"2021-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25333180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcoma","authors":"F. Traub, D. Andreou, M. Niethard, C. Tiedke, M. Werner, P. Tunn","doi":"10.1007/978-981-15-9414-4","DOIUrl":"https://doi.org/10.1007/978-981-15-9414-4","url":null,"abstract":"","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-981-15-9414-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51108782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clear Cell Chondrosarcoma: Clinical Characteristics and Outcomes in 15 Patients","authors":"J. Flint, A. Conley, M. L. Rubin, Lei Feng, P. Lin, Bryan S Moon, J. Bird, R. Satcher, Valerae O. Lewis","doi":"10.1155/2020/2386191","DOIUrl":"https://doi.org/10.1155/2020/2386191","url":null,"abstract":"Background. Clear cell chondrosarcoma (CCC) represents less than 6% of all chondrosarcomas, and thus, our understanding of this rare entity is limited. Analyzing clinical characteristics and treatment patterns, thus increasing our knowledge, may improve treatment strategy. We review our institutional experience with 15 patients, including one case with dedifferentiation. Methods. A retrospective review was conducted in CCC patients treated at our institution from 1996 to 2015, with at least 2-year follow-up. Descriptive statistics and Kaplan–Meier survival analyses were performed. Results. Of 19 patients identified, 15 patients had at least 2-year follow-up and were included. The median age at diagnosis was 43 years. 80% were male. The most common presenting signs were pain (12 patients; 80%) and fracture (2 patients; 13.3%). The most common site was proximal femur (8 patients; 53%). All patients had MSTS Stage I disease. Primary treatment included wide resection in 10 patients (67%) and intralesional or marginal resection in 5 patients (33%). Three patients died of disease during the study period, 1 with dedifferentiation of recurrent CCC. The median time to death from disease was 15.3 years (95% CI: (14.2; NA)). The median time to either recurrence or death was 7.73 years for patients who had intralesional/marginal resection and 16.44 years for patients with wide resection (HR (wide vs. intralesional/marginal) = 0.21, 95% CI: (0.04; 1.18), \u0000 \u0000 p\u0000 =\u0000 0.053\u0000 \u0000 ). The median time to recurrence or death was significantly shorter for patients not initially treated at a sarcoma center (\u0000 \u0000 p\u0000 =\u0000 0.01\u0000 \u0000 ). Conclusions. CCC is a rare entity, and our understanding of it is still evolving. We observed a higher recurrence rate for intralesional or marginal resection, and wide resection alone remains the mainstay of treatment. Better outcomes were observed in patients initially treated by trained musculoskeletal oncologists. Due to the propensity of CCC to recur decades after initial resection, lifelong surveillance is recommended.","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46686545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Soft Tissue Tumour Pathology","authors":"Vanessa Tran, J. Slavin","doi":"10.1007/978-981-15-9414-4_7","DOIUrl":"https://doi.org/10.1007/978-981-15-9414-4_7","url":null,"abstract":"","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48925501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone Tumour Pathology","authors":"Vanessa Tran, J. Slavin","doi":"10.1007/978-981-15-9414-4_6","DOIUrl":"https://doi.org/10.1007/978-981-15-9414-4_6","url":null,"abstract":"","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44660941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Resection Margins in Bone Tumor Surgery.","authors":"Corentin Malherbe,&nbsp;Bernard Crutzen,&nbsp;Jean Schrooyen,&nbsp;Giovanni Caruso,&nbsp;Frédéric Lecouvet,&nbsp;Christine Detrembleur,&nbsp;Thomas Schubert,&nbsp;Pierre-Louis Docquier","doi":"10.1155/2020/5289547","DOIUrl":"https://doi.org/10.1155/2020/5289547","url":null,"abstract":"<p><p>Limb salvage surgery is now the preferred procedure for bone tumor surgery. To decrease the risk of local recurrence, it is crucial to obtain adequate resection margins. The obtained margins must be evaluated postoperatively because they influence what treatment is given subsequently when margins are not adequate (e.g., surgical revision and radiotherapy). The study aims to evaluate margin assessment of tumor specimen by MRI compared to conventional histology (to establish the viability of using MRI) and assess the accuracy of a patient-specific instrument when narrow margins were aimed. The resection margins in 12 consecutive patients that were operated on for bone tumor resection were prospectively analyzed using three methods: MRI of the resection specimen, macroscopic evaluation of specimen slices, and microscopic pathological evaluation. The assessments were qualitative (R0, R1, and R2) and quantitative (distance in mm). MRI, macroscopic, and microscopic margins generated similar results for both the qualitative (all resections were R0) and quantitative assessments. The median error in safe margins was 2 mm with a surgical guide (PSI) and 5 mm without a surgical guide. Local recurrences were not detected after a mean follow-up period of 3.7 years (range, 2.1-5 years); however, four patients died during the study. In conclusion, MRI is a valuable tool for assessing safe margins. When specimens are not available for pathological assessment (e.g., extracorporeally irradiated autograft or autoclaved autograft), MRI could be used to evaluate margins. In particular, when tumor volume is high, MRI could also help to focus the pathological examination on areas of concern.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2020 ","pages":"5289547"},"PeriodicalIF":0.0,"publicationDate":"2020-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/5289547","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38854962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biopsy","authors":"Peter F. M. Choong","doi":"10.1007/978-981-15-9414-4_5","DOIUrl":"https://doi.org/10.1007/978-981-15-9414-4_5","url":null,"abstract":"","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51108875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}